# 21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.

21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses., “Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and…”, is a CFR section of [21 CFR Part 312, Subpart E—Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses](https://ontology.bommaritollc.com/id/01a0f094-b5ed-703e-98ee-c9a03550ea01); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f094-b437-7426-9a1d-f0a9f3d3e1aa) › [21 CFR Chapter I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES](https://ontology.bommaritollc.com/id/01a0f094-b455-74b7-9458-ed95d7b5ea58) › [21 CFR Chapter I, Subchapter D—DRUGS FOR HUMAN USE](https://ontology.bommaritollc.com/id/01a0f094-b5e4-722f-99b0-5c1856aef2a9) › [21 CFR Part 312—Investigational new drug application](https://ontology.bommaritollc.com/id/01a0f094-b84c-75c3-a0c0-d388d85f1044) › [21 CFR Part 312, Subpart E—Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses](https://ontology.bommaritollc.com/id/01a0f094-b5ed-703e-98ee-c9a03550ea01)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [cfr-section 21 CFR 312.84](https://ontology.bommaritollc.com/id/01a0f094-c4ae-77a9-9fac-9f0fdd50e2fe)
- `eli:cites`:
  - [21 CFR Part 314—Applications for FDA approval to market a new drug](https://ontology.bommaritollc.com/id/01a0f094-b84d-7031-b149-cb632d656858)
  - [21 CFR Part 601—Licensing](https://ontology.bommaritollc.com/id/01a0f094-b882-764a-a051-b44410b6e848)
  - [21 CFR 312.80 Purpose.](https://ontology.bommaritollc.com/id/01a0f094-c4aa-719e-8422-b76257b4db73)
  - [21 CFR 312.82 Early consultation.](https://ontology.bommaritollc.com/id/01a0f094-c4ac-751a-b3e2-b64f55ace1b2)
  - [21 CFR 314.101 Filing an NDA and receiving an ANDA.](https://ontology.bommaritollc.com/id/01a0f094-c4cd-75f0-b892-95a5845f7ce4)
  - [21 CFR 314.110 Complete response letter to the applicant.](https://ontology.bommaritollc.com/id/01a0f094-c4d3-753b-8cc4-f819dd58f448)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/CFR-2025-title21-vol1](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b0afe143f9)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f094-e317-701b-b1cc-06ef86b8a57c)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d0-c4e4-767c-9e09-693801ad1f73)
  - [evidence from https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f17-67b7-727a-802d-e8c4ecfefc54)
- `schema:isPartOf`: [21 CFR Part 312, Subpart E—Drugs Intended to Treat Life-threatening and Severely-debilitating Illnesses](https://ontology.bommaritollc.com/id/01a0f094-b5ed-703e-98ee-c9a03550ea01)
- `schema:legislationIdentifier`: 21 CFR 312.84
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [CFR section](https://ontology.bommaritollc.com/vocab/leg/cfrSection)
- `schema:name`: Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses
- `schema:url`: [https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details](https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.

## Elsewhere

- [Official page](https://www.govinfo.gov/link/cfr/21/312?sectionnum=84&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/CFR-2025-title21-vol1) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (1; `eli:cites`):
  - [21 CFR 314.125 Refusal to approve an NDA.](https://ontology.bommaritollc.com/id/01a0f094-c4d5-7607-9f58-27d7aa7b26b8)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb)
Cite as: 21 CFR 312.84 Risk-benefit analysis in review of marketing applications for drugs to treat life-threatening and severely-debilitating illnesses.. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f094-c4ad-70e9-8fec-e2b1899763eb
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
